Inclusion Criteria:

          1. Signed, informed consent

          2. Age 18 or older (for all treatment locations with exception of Taiwan), or age 20 or
             older (Taiwan only)

          3. Pathologically or cytologically-confirmed, advanced-stage hepatocellular carcinoma
             without prior systemic treatment except for prior immunotherapy and Child-Pugh liver
             function class A appropriate for treatment with sorafenib

          4. Measurable disease according to modified Response Evaluation Criteria in Solid Tumors
             criteria (mRECIST)

          5. Eastern Cooperative Oncology Group (ECOG) performance status: 0 to 1

          6. Adequate laboratory parameters including:

               1. Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 3.0 x
                  upper limit of normal (ULN), or AST and ALT ≤ 5.0 x ULN if liver function
                  abnormalities are due to underlying malignancy

               2. Total serum bilirubin ≤ 2.0 x ULN (except for subjects with documented Gilbert's
                  syndrome who have a limit of ≤ 3.0 x ULN)

               3. Absolute neutrophil count (ANC):1500/µL

               4. Platelets: 90,000/µL

               5. Hemoglobin: 9.0 g/dL

               6. Serum creatinine ≤ 2.0 x ULN or creatinine clearance of ≥ 50 mL/min

               7. Serum albumin ≥ 3.0 g/dL

               8. International normalized ratio (INR) ≤ 1.4

               9. Prothrombin Time (PT)/ Activated Partial Thromboplastin Time (aPTT) ≤ 1.2 x ULN

          7. QTc interval (using Fridericia correction) of ≤ 470 msec (QTc interval may be derived
             from up to 3 separate EKGs performed at least 5 minutes apart)

          8. Willingness to participate in collection of pharmacokinetic and other exploratory
             blood collection as defined in the protocol

          9. Willingness to use adequate contraception throughout study and for a period of 3
             months after last dose of CVM-1118

        Exclusion Criteria:

          1. Major surgery (other than diagnostic surgery) or radiation therapy within 28 days of
             starting study treatment

          2. Prior systemic immunotherapy for hepatoma within 28 days of starting study treatment

          3. Systemic anticancer therapy (e.g., chemotherapy, hormonal, investigational, biological
             therapies) within 28 days (or fewer than 5 half-lives, whichever is shorter) of
             starting study treatment except for ongoing hormonal therapy administered for control
             of a second cancer (e.g., breast or prostate cancer)

          4. Receipt of a CYP3A4 inducer less than 28 days or 5 half-lives of the CYP3A4 inducer
             prior to the first day of sorafenib administration

          5. Other known active cancer(s) likely to require treatment in the next two (2) years or
             likely to impact the assessment of any study endpoints

          6. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic
             therapy (e.g., subjects with known HBV or HCV infections controlled on antivirals are
             allowed)

          7. Known Central Nervous system (CNS) metastases unless appropriately treated and
             neurologically stable for ≥ 4 weeks off steroids

          8. Pregnant or currently breast-feeding

          9. Known HIV-positive

         10. Patients with impaired gastrointestinal (GI) diseases that may significantly alter the
             absorption of oral medications

         11. Psychiatric illness/social situations that would interfere with compliance with study
             requirements

         12. History of clinically significant cardiovascular abnormalities such as uncontrolled
             hypertension, congestive heart failure (New York Heart Association classification ≥
             2), unstable angina, poorly controlled arrhythmias, myocardial infarction within 6
             months of study entry

         13. Other severe acute or chronic medical or psychiatric conditions or laboratory
             abnormalities that would impart, in the judgement of the PI and/or Sponsor, excess
             risk associated with study participation or study drug administration, which would
             make the subject inappropriate for entry into this study